Biogen Inc. closed 46.82% short of its 52-week high of $238.00, which the company achieved on July 12th.

OKLAHOMA CITY — As Game 1 of the NBA Finals began at Paycom Center, discerning fans on social media asked: “Why aren’t there NBA Finals logos on the court?” For the most part – there are ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...

5:53 AM ESTHealth Care Sage rejects Biogen’s buyout offer, but says it's open to deals Sage rejects Biogen’s buyout offer, but says it's open to deals ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making a comeback. After a lackluster showing in 2024 extended a yearslong ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.